Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
Matthew David Hellmann, Jamie E. Chaft, William N. William et al. · The Lancet Oncology · 2014
Cited by 642 works. doi:10.1016/s1470-2045(13)70334-6
Authors
- Matthew David Hellmann
- Jamie E. Chaft
- William N. William
- Valerie W. Rusch
- Katherine M.W. Pisters
- Neda Kalhor
- Apar Pataer
- William David Travis
- Stephen G. Swisher
- Mark G. Kris
References
- Surrogate endpoints in clinical trials: Definition and operational criteria
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
- Surrogate End Points in Clinical Trials: Are We Being Misled?
- Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
- Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy
- Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
- A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes